Literature DB >> 28390972

Targeting cell surface HIV-1 Env protein to suppress infectious virus formation.

Arangassery Rosemary Bastian1, Charles G Ang2, Kantharaju Kamanna3, Farida Shaheen4, Yu-Hung Huang3, Karyn McFadden3, Caitlin Duffy3, Lauren D Bailey3, Ramalingam Venkat Kalyana Sundaram2, Irwin Chaiken5.   

Abstract

HIV-1 Env protein is essential for host cell entry, and targeting Env remains an important antiretroviral strategy. We previously found that a peptide triazole thiol KR13 and its gold nanoparticle conjugate AuNP-KR13 directly and irreversibly inactivate the virus by targeting the Env protein, leading to virus gp120 shedding, membrane disruption and p24 capsid protein release. Here, we examined the consequences of targeting cell-surface Env with the virus inactivators. We found that both agents led to formation of non-infectious virus from transiently transfected HEK293T cells. The budded non-infectious viruses lacked Env gp120 but contained gp41. Importantly, budded virions also retained the capsid protein p24, in stark contrast to p24 leakage from viruses directly treated by these agents and arguing that the agents led to deformed viruses by transforming the cells at a stage before virus budding. We found that the Env inactivators caused gp120 shedding from the transiently transfected HEK293T cells as well as non-producer CHO-K1-gp160 cells. Additionally, AuNP-KR13 was cytotoxic against the virus-producing HEK293T and CHO-K1-gp160 cells, but not untransfected HEK293T or unmodified CHO-K1 cells. The results obtained reinforce the argument that cell-surface HIV-1 Env is metastable, as on virus particles, and provides a conformationally vulnerable target for virus suppression and infectious cell inactivation.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Gold nanoparticles; HIV-1; Infected cell inactivation; Multivalency; Peptide triazoles

Mesh:

Substances:

Year:  2017        PMID: 28390972      PMCID: PMC5555212          DOI: 10.1016/j.virusres.2017.04.003

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  11 in total

1.  Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.

Authors:  Alyssa C Biorn; Simon Cocklin; Navid Madani; Zhihai Si; Tijana Ivanovic; James Samanen; Donald I Van Ryk; Ralph Pantophlet; Dennis R Burton; Ernesto Freire; Joseph Sodroski; Irwin M Chaiken
Journal:  Biochemistry       Date:  2004-02-24       Impact factor: 3.162

2.  Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120.

Authors:  Arangassery R Bastian; Karyn McFadden; Caitlin Duffy; Srivats Rajagopal; Mark R Contarino; Elisabeth Papazoglou; Irwin Chaiken
Journal:  ChemMedChem       Date:  2011-06-28       Impact factor: 3.466

3.  Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.

Authors:  Karyn McFadden; Patricia Fletcher; Fiorella Rossi; Muddagowda Umashankara; Vanessa Pirrone; Srivats Rajagopal; Hosahudya Gopi; Fred C Krebs; Julio Martin-Garcia; Robin J Shattock; Irwin Chaiken
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

4.  Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.

Authors:  Arangassery Rosemary Bastian; Aakansha Nangarlia; Lauren D Bailey; Andrew Holmes; R Venkat Kalyana Sundaram; Charles Ang; Diogo R M Moreira; Kevin Freedman; Caitlin Duffy; Mark Contarino; Cameron Abrams; Michael Root; Irwin Chaiken
Journal:  J Biol Chem       Date:  2014-11-04       Impact factor: 5.157

5.  Peptide triazole inactivators of HIV-1: how do they work and what is their potential?

Authors:  Irwin Chaiken; Adel A Rashad
Journal:  Future Med Chem       Date:  2015-11-24       Impact factor: 3.808

6.  Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter.

Authors:  Adel A Rashad; Ramalingam Venkat Kalyana Sundaram; Rachna Aneja; Caitlin Duffy; Irwin Chaiken
Journal:  J Med Chem       Date:  2015-09-11       Impact factor: 7.446

7.  Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.

Authors:  David C Montefiori
Journal:  Curr Protoc Immunol       Date:  2005-01

8.  Cell surface expression of the HIV-1 envelope glycoproteins is directed from intracellular CTLA-4-containing regulated secretory granules.

Authors:  Luis R Miranda; Brian C Schaefer; Abraham Kupfer; Zixin Hu; Alex Franzusoff
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

9.  An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors.

Authors:  Alon Herschhorn; Andres Finzi; David M Jones; Joel R Courter; Akihiro Sugawara; Amos B Smith; Joseph G Sodroski
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

10.  Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.

Authors:  Arangassery Rosemary Bastian; Mark Contarino; Lauren D Bailey; Rachna Aneja; Diogo Rodrigo Magalhaes Moreira; Kevin Freedman; Karyn McFadden; Caitlin Duffy; Ali Emileh; George Leslie; Jeffrey M Jacobson; James A Hoxie; Irwin Chaiken
Journal:  Retrovirology       Date:  2013-12-13       Impact factor: 4.602

View more
  2 in total

1.  Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.

Authors:  Adel A Rashad; Kriti Acharya; Ann Haftl; Rachna Aneja; Alexej Dick; Andrew P Holmes; Irwin Chaiken
Journal:  Org Biomol Chem       Date:  2017-09-26       Impact factor: 3.876

Review 2.  New insights into application of nanoparticles in the diagnosis and screening of novel coronavirus (SARS-CoV-2).

Authors:  Abhimanyu Tharayil; R Rajakumari; Amresh Kumar; Manabendra Dutta Choudhary; Parth Palit; Sabu Thomas
Journal:  Emergent Mater       Date:  2021-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.